BAP1 and cancer: To assess utility of αMDLA in MPM cancer cells, we selected the paired MESO-8T (BAP1-altered, ASS1-moderate) and MESO-12T (BAP1-normal, ASS1-low) cells, and another pair of low passage epithelioid cells that have similar tumor suppressor status (lacking CDKN2A but not NF2, Supplementary Fig. S10) and mizoribine sensitivity (Supplementary Fig. S15): MESO-29T (BAP1-normal, ASS1-undetectable) and MESO-23T (BAP1-altered, ASS1-moderate).